RECURRENT BREAST CARCINOMA

This early-phase trial tests a DNA vaccine called STEMVAC in 42 people with advanced HER2-negative breast cancer. The vaccine is designed to help the immune system recognize and attack cancer stem cells, which are often resistant to standard treatments. The main goals are to chec…

This study tests whether combining the immunotherapy drug avelumab with other medications can help people with advanced triple-negative breast cancer. About 145 adults with stage IV or inoperable breast cancer will receive one of several drug combinations. The goal is to see if t…

This early-phase trial tested the safety and best dose of combining veliparib with the chemotherapy drug carboplatin in 44 people with HER2-negative breast cancer that had spread. The goal was to see if veliparib could stop cancer cells from repairing damage caused by carboplatin…

This study tests whether adding a drug called copanlisib to the usual two-drug therapy (fulvestrant and abemaciclib) works better for people with a certain type of advanced breast cancer (hormone receptor-positive, HER2-negative) that has spread. The trial involves 24 participant…

This early-phase trial studies two drug combinations (olaparib plus vistusertib or olaparib plus capivasertib) in people with recurrent endometrial, triple-negative breast, ovarian, or related cancers. The main goal is to find the safest dose and understand side effects. About 15…

This early-phase trial tested a combination of two drugs—low-dose cyclophosphamide and veliparib—in 35 people with HER2-negative breast cancer that had spread or couldn't be removed by surgery. The goal was to find the safest dose and see if the combo could shrink tumors. While n…

This study tests whether a newer drug, Z-Endoxifen, works better than the standard drug tamoxifen for postmenopausal women with a certain type of advanced breast cancer (ER+/HER2-). The cancer has spread or come back despite prior hormone therapy. About 81 women will be randomly …

This study tested whether adding the drug entinostat to standard hormone therapy (exemestane) helps people with advanced hormone receptor-positive breast cancer live longer without their cancer growing. About 600 adults with breast cancer that had spread or come back took part. T…

This study tests if a form of estrogen called estradiol can help people with a specific type of triple negative breast cancer that has spread. The cancer must have a protein called ER beta, which may make it sensitive to estrogen. Researchers want to see if the treatment can shri…

This early-phase study tested a drug called Z-endoxifen in 62 women with a type of breast cancer that has spread or come back. The goal was to find the safest dose and see how well it blocks estrogen, which can fuel cancer growth. Participants had estrogen receptor-positive (ER+)…

This early-phase study tests a drug called berzosertib combined with radiation therapy for people with certain types of breast cancer that no longer respond to chemotherapy. The goal is to find the safest dose and see if the combination can shrink or stabilize tumors better than …

This study looks at whether regularly measuring the amount of paclitaxel (a chemotherapy drug) in the blood can help doctors give the right dose to kill cancer while limiting nerve damage. About 22 adults with various solid tumors (like lung, breast, or ovarian cancer) will have …

This study tests whether analyzing the genes in a patient's tumor can help doctors choose a more effective treatment. Over 6,400 adults with advanced or hard-to-treat cancers (solid tumors, lymphoma, or myeloma) had their tumors genetically screened. Those with specific genetic c…

This study aims to create a large collection of blood and tumor samples from 300 people whose breast cancer has spread or returned. By linking these samples with medical information, researchers hope to learn why the cancer spreads and why people respond differently to treatments…